Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Leukemia, Myeloid, Acute 23Myelodysplastic Syndromes 14Leukemia, Myelomonocytic, Chronic 7Myeloproliferative Disorders 4Myelodysplastic-Myeloproliferative Diseases 2Leukemia, Biphenotypic, Acute 2Anemia, Refractory, with Excess of Blasts 2Triple Negative Breast Neoplasms 1Thrombocythemia, Essential 1Systemic Mastocytosis With an Associated Hematologic Neoplasm 1Prostatic Neoplasms 1Primary Myelofibrosis 1Polycythemia Vera 1Neurofibrosarcoma 1Neuroendocrine Tumors 1Mesothelioma, Malignant 1Mesothelioma 1Melanoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Leukemia, Myeloid, Chronic-Phase 1Hodgkin Disease 1GATA2 Deficiency 1Cytopenia 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1BRCA1 Mutation 1

Interventions

pembrolizumab 18Nivolumab 13avelumab 10Ipilimumab 7Specimen Handling 6cemiplimab 5atezolizumab 5Magnetic Resonance Spectroscopy 5Biopsy 5Radiotherapy 3Cyclophosphamide 3prednylidene 2poly ICLC 2lutetium Lu 177 dotatate 2fludarabine phosphate 2fludarabine 2durvalumab 2deltacortene 2aldesleukin 2Radiosurgery 2Prednisone 2Interleukin-2 2Immunoglobulin G 2Docetaxel 2CTLA-4 Antigen 2Bevacizumab 2tocilizumab 1talimogene laherparepvec 1sargramostim 1relatlimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Merkel Cell × decitabine and cedazuridine drug combination × 1 year × Clear all
NCT07472322 2026-05-29

ASTX727 & Retifanlimab-dlwr for Advanced Merkel Cell After Progression on Anti-PD-(L)1

University of Wisconsin, Madison

Phase 1/2 Not yet recruiting
31 enrolled
Dermatologic

Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡